Our Blog

Noxopharm (ASX:NOX) LuPIN trial in prostate cancer

25 Feb 2020 – Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company’s LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.


Source: Finance News Network

Share this post